Otsuka Pharmaceuticals

Showing 3 posts of 3 posts found.

Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug

May 11, 2023
Medical Communications FDA, Lundbeck, Neurology, Otsuka Pharmaceuticals, alzheimer's disease, dementia

Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US Food and Drug Administration (FDA) …

NICE recommends Otsuka’s Lupkynis (voclosporin) in combination treatment for active lupus nephritis

May 4, 2023
Medical Communications MHRA, NICE, Nephrology, Otsuka Pharmaceuticals, lupus nephritis

Otsuka Pharmaceuticals has announced that the National Institutes for Health and Care Excellence (NICE) has recommended Lupkynis (voclosporin) in combination …


Otsuka to acquire Neurovance in potential $250 million deal

March 6, 2017
Sales and Marketing ADHD, Neurovance, Otsuka Pharmaceuticals

Otsuka Pharmaceuticals, a pharmaceutical firm with headquarters in Japan, has agreed to pay a potential $250 million in a deal …

Latest content